Form 4: Harmony Biosciences CCO Granted Equity Awards

Harmony Biosciences' Chief Commercial Officer, Adam H. Zaeske, received significant equity awards, including stock options and restricted stock units, tied to future service.

Summary

• Adam H. Zaeske, Chief Commercial Officer of Harmony Biosciences Holdings, Inc. (HRMY), was granted equity awards on January 22, 2026.
• The awards include 56,900 stock options with an exercise price of $36.76 per share.
• The stock options vest with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date (January 22, 2030).
• The stock options have an expiration date of January 22, 2036.
• Additionally, 16,200 Restricted Stock Units (RSUs) were granted.
• The RSUs will vest in four equal annual installments beginning on January 22, 2027.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
• All vesting is subject to Mr. Zaeske's continued service through each applicable vesting date.

Sentiment

Score: 6

Explanation: The filing details routine executive equity grants, which are generally positive for aligning management incentives with shareholder interests and for executive retention, without indicating any immediate negative implications for the company's operations or financial health.

Positives

• The equity grants align the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both stock options and restricted stock units promote executive retention by requiring continued service over several years.
• The grants are a standard component of executive compensation, reflecting a commitment to attracting and retaining key talent.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity compensation.

Industry Context

Equity compensation, such as stock options and restricted stock units, is a common practice across the biotechnology and pharmaceutical industries to incentivize and retain key executives. These awards are typically tied to service-based vesting conditions, aligning executive interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of stock options and restricted stock units with multi-year vesting schedules, is consistent with typical executive compensation packages observed in the biotechnology and pharmaceutical sectors.
• The vesting schedule, with an initial cliff and subsequent ratable vesting, is a standard mechanism used by companies like Pfizer, Merck, and Amgen to ensure executive retention and long-term commitment.

Stakeholder Impact

• Shareholders: The grants align the Chief Commercial Officer's incentives with shareholder value creation, potentially leading to improved long-term performance. However, they also represent potential future dilution upon exercise/vesting.
• Employees: The compensation structure for a key executive can serve as a benchmark or motivator for other employees, reinforcing the company's compensation philosophy.
• Management: The awards provide significant long-term incentives and retention mechanisms for the Chief Commercial Officer.

Next Steps

• Continued service of Adam H. Zaeske to meet vesting conditions for stock options and restricted stock units.
• Periodic vesting of stock options and restricted stock units on their respective schedules.

Key Dates

Keywords

Harmony Biosciences, HRMY, Stock Options, Restricted Stock Units, Equity Awards, Executive Compensation, Insider Transaction, Form 4